Controlled Synthesis of the FeB Nanometallic Glasses with Stronger Electron Donating Capability to Activate Molecular Oxygen for the Enhanced Ferroptosis Therapy
Considering the strong electron-donating ability and the superior biocompatibility, the integration of zero-valent iron nanostructure Fe (electron-reservoir) and zero-valent boron nanostructure B offers great promise for fabricating novel ferroptosis nanoagents. Nevertheless, the controlled and faci...
Gespeichert in:
Veröffentlicht in: | Advanced healthcare materials 2024-12, p.e2403582 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Considering the strong electron-donating ability and the superior biocompatibility, the integration of zero-valent iron nanostructure Fe
(electron-reservoir) and zero-valent boron nanostructure B
offers great promise for fabricating novel ferroptosis nanoagents. Nevertheless, the controlled and facile synthesis of alloyed Fe
and B
nanostructure-FeB nanometallic glasses (NMGs) has remained a long-standing challenge. Herein, a complexion-reduction strategy is proposed for the controlled synthesis of FeB NMGs with greater electron donating capacity to activate the molecular oxygen for improved ferroptosis therapy. In-depth mechanism reveales that the complexion-reduction strategy effectively prevent the long-range diffusion of Fe
, resulting in the amorphous alloyed Fe
and B
nanostructure-FeB nanoparticles (FeB NPs). The FeB NPs display stronger electron donating capability and electron transfer rate 9.4 times higher than that of the Fe
NPs, which effectively activate the molecular oxygen to produce ∙O
, H
O
and ∙OH. The in vitro cellular experiments confirm the FeB-ss-SiO₂ NPs (encapsulation with SiO
outlayer containing -S-S- bonds) demonstrates the enhanced ferroptosis. The tumor-bearing mice models shows that FeB-ss-SiO₂ NPs exhibited superior biocompatibility and tumor inhibition effect (inhibition rate of 73%), which improve the overall survival rate for 30 days post-treatment. This study will provide an innovative way to design therapeutic nanoagents for cancer treatments. |
---|---|
ISSN: | 2192-2640 2192-2659 |
DOI: | 10.1002/adhm.202403582 |